International Psoriasis Council

Name

International Psoriasis Council

Legal name

International Psoriasis Council

Website

https://psoriasiscouncil.org

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Medical Education and Research (Dermatology)

NAICS

Business Associations (813910)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Psoriasis medical education
• Dermatology research
• Clinical assessment tools
• Continuing medical education
• Psoriasis treatment guidelines

Headquarters

HQ city

St Louis

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Corporate Memberships: Pharmaceutical companies support IPC through corporate membership tiers (Diamond, Platinum, Gold, Silver, Bronze) with current members including AbbVie, Johnson & Johnson, Eli Lilly, Takeda, Novartis, LEO, UCB, Almirall, Sun Pharma, Amgen, Alumis, Arcutis Biotherapeutics, and Oruka Therapeutics.
2. Donations: IPC accepts donations through PayPal, checks, and bank transfers to support psoriasis research and medical education.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

The International Psoriasis Council (IPC) is a US-based nonprofit that provides free medical education, clinical resources, and research programs for healthcare professionals treating psoriasis. It maintains a global network of 200+ volunteer psoriasis experts across 51 countries who develop consensus statements, treatment guidelines, clinical assessment tools, and educational content. IPC also runs the International Fellowship Program for early-career dermatologists and partners on initiatives such as the Global Psoriasis Atlas.

Product overview

The International Psoriasis Council offers a comprehensive portfolio of educational services, research resources, and clinical tools rather than a traditional product. The core offerings include: a Resource Library containing publications, videos, and congress reports; Clinical Assessment Tools for measuring psoriasis severity; specialized initiatives addressing Disease Severity Classification, Diverse Skin Tones, Pediatric Psoriasis, and Digital Health; the Global Psoriasis Atlas project; the International Fellowship Program; Regional Masterclasses; and a searchable Expert Network Directory. These services work together to advance psoriasis knowledge, improve patient care, and support healthcare professionals worldwide through education, research collaboration, and the development of clinical guidance.

Differentiator

Problem solved

Functional benefit

Products and services

• IPC Resource Library A comprehensive digital library of articles, congress reports, publications, videos, expert commentaries, symposium recordings, and educational materials covering psoriasis research, treatment guidelines, and clinical assessments, provided free to healthcare professionals worldwide.
• Clinical Assessment Tools A collection of validated measurement tools for psoriasis management and clinical trials including PASI, DLQI, PGA, CDLQI, NAPSI, PEST, and specialized assessments for special populations, made available to clinicians and researchers.
• Disease Severity Reclassification Framework IPC's consensus framework for categorizing psoriasis severity that divides patients into candidates for either topical or systemic therapy based on three criteria: body surface area involvement, high-impact site involvement, or topical treatment failure.
• Global Psoriasis Atlas A joint project with the International League of Dermatological Societies (ILDS) and the International Federation of Psoriasis Associations (IFPA) creating the first-ever global database on psoriasis burden, incidence, and prevalence across all countries and regions.
• IPC International Fellowship Program A program providing young dermatologists and researchers full access to IPC's expert network knowledge, fostering the next generation of psoriasis leaders through mentorship and education, with the 2026 cycle supported by Diamond Corporate Member Johnson & Johnson.
• Regional Masterclasses A 10-hour curriculum delivered by international and regional experts designed for early to mid-career dermatologists improving their expertise in caring for psoriasis patients, delivered through regional outreach working groups.
• IPC Rapid Communications Concise expert publications providing timely insights on emerging developments in psoriasis research, clinical practice, and health policy, typically under 500 words with up to five references.
• Expert Network Directory A searchable directory of IPC's global network of over 200 psoriasis experts from 51 countries, including Board Members, Councilors, Junior Councilors, and Councilors Emeritus specializing in various areas of psoriasis research and care.

Quantifiable outcome

• IPC's disease severity reclassification has been increasingly reflected in clinical trial designs, national guidelines, and treatment recommendations across multiple countries
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Seven partnerships are on record, tiered core and minor.

• International Federation of Psoriasis Associations (IFPA)coreStrategic or Co-development PartnerIPC partners with IFPA on multiple initiatives including the Global Psoriasis Atlas (GPA), Recategorization of Disease Severity, Telemedicine, and Diverse Skin Tones projects. IFPA is a nonprofit founded in 1971 that unites national and regional psoriasis associations worldwide.
• National Psoriasis Foundation (NPF)coreStrategic or Co-development PartnerUS-based nonprofit dedicated to finding a cure for psoriasis and psoriatic arthritis. IPC collaborates with NPF on joint position statements including routine testing for latent tuberculosis infection.
• Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)coreStrategic or Co-development PartnerInternational nonprofit consortium founded in 2003 with over 1,000 rheumatologists, dermatologists, radiologists, epidemiologists, geneticists, and patient research partners. IPC and GRAPPA jointly lead the Difficult-to-Treat/Treatment Refractory Psoriasis Consensus Initiative.
• International League of Dermatological Societies (ILDS)coreStrategic or Co-development PartnerFounded in 1935, ILDS represents dermatology at the highest level with over 180 Member Societies from more than 80 countries representing 200,000+ dermatologists. Joint project partner on the Global Psoriasis Atlas.
• International Eczema Council (IEC)minorStrategic or Co-development PartnerGlobal nonprofit organization founded in 2014 led by dermatology and allergy experts in atopic dermatitis, with 180+ Councilors and Associates from over 35 countries.
• Pan-American League of Associations for Rheumatology (PANLAR)minorStrategic or Co-development PartnerFounded in 1944, PANLAR brings together national rheumatology societies, healthcare professionals, and patient groups from across the Americas to advance research, education, and clinical care.
• SOLAPSO (Sociedad Latinoamericana de Psoriasis)minorStrategic or Co-development PartnerFounded in Buenos Aires, Argentina in July 2008 by dermatologists committed to advancing psoriasis understanding, diagnosis, and treatment in Latin America.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• National Psoriasis Foundation: US-based nonprofit dedicated to finding a cure for psoriasis and psoriatic arthritis. NPF directly partners with IPC on joint position statements (e.g., latent tuberculosis testing) and shares the same mission of improving care and research for psoriasis patients, making it the closest like-for-like peer.
• International Federation of Psoriasis Associations (IFPA): Nonprofit founded in 1971 uniting national and regional psoriasis associations worldwide. IFPA is a core IPC partner on the Global Psoriasis Atlas and multiple initiatives, and is structurally identical in mission and global reach — the most directly comparable peer organization.
• Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): International nonprofit consortium of 1,000+ rheumatologists, dermatologists, and researchers focused on psoriasis and psoriatic arthritis. GRAPPA jointly leads the Difficult-to-Treat/Treatment Refractory Psoriasis Consensus Initiative with IPC, making it a direct peer in research and consensus activity.

Broad incumbents

• International League of Dermatological Societies (ILDS): Founded in 1935, ILDS represents over 180 dermatology member societies from 80+ countries covering 200,000+ dermatologists globally. As IPC's joint partner on the Global Psoriasis Atlas, ILDS is a broader dermatology umbrella that sponsors also fund, putting it in partial overlap with IPC's category.
• American Academy of Dermatology (AAD): The largest US dermatology professional association with broad CME, guidelines, and member services. AAD overlaps with IPC on psoriasis education and competes for the same clinician engagement and pharma sponsorship budget, but at a much larger scale across all dermatologic conditions.

Regional players

• European Academy of Dermatology and Venereology (EADV): Leading European dermatology organization running congresses, education, and research programs. EADV serves similar audiences as IPC but with a broader dermatology scope and primary geographic focus on Europe, making it a regional incumbent peer in the IPC ecosystem.
• Pan American League of Associations for Rheumatology (PANLAR): Founded in 1944, PANLAR brings together rheumatology societies across the Americas. As an IPC partner serving overlapping clinician audiences on psoriatic arthritis, PANLAR is a regional peer with comparable association structure but different disease focus.
• Sociedad Latinoamericana de Psoriasis (SOLAPSO): Latin American psoriasis society founded in Buenos Aires in 2008. SOLAPSO is a direct regional peer to IPC's Latin American Working Group activities and competes for the same regional pharma support, clinician engagement, and psoriasis education mandate in the region.

Emerging players

• International Eczema Council (IEC): Global nonprofit founded in 2014 with 180+ Councilors and Associates across 35+ countries focused on atopic dermatitis. IEC shares IPC's structure as a council of leading experts producing education and consensus, and competes for the same clinician-attention and pharma-sponsorship pool in adjacent inflammatory skin disease.

Others

• Coalition of Skin Diseases: Umbrella advocacy organization representing patient groups for multiple skin diseases including psoriasis. While not a direct competitor, the Coalition overlaps with IPC's mission to improve patient outcomes and serves as an adjacent advocacy body that sponsors may fund alongside IPC.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/IpcPs
• YouTubeyoutube.com/user/ThePsoriasisCouncil
• Facebookfacebook.com/ipcinternationalpsoriasiscouncil
• LinkedInlinkedin.com/company/international-psoriasis-council
• Instagraminstagram.com/internationalpsoriasiscouncil

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about International Psoriasis Council